Cure My Disease

Don't miss your cure!

 Log in / Sign up

Washing kidneys to stop hidden virus: new trial aims to make transplants safer

NCT ID NCT07488481

Not yet recruiting Disease control Sponsor: University Health Network, Toronto Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests whether treating a donor kidney with a drug called SYN002 before transplant can safely reduce the risk of passing cytomegalovirus (CMV) to the recipient. About 12 adults waiting for a kidney transplant will receive a treated organ. The main goal is to see if the kidney works well after transplant and if the treatment is safe.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for END STAGE RENAL DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

end stage renal failure cytomegalovirus infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CYTOMEGALOVIRUS (CMV) INFECTION KIDNEY TRANSPLANT RECIPIENT

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University Health Network, Toronto General Hospital, Ajmera Transplant Centre

    Toronto, Ontario, M5G 2N2, Canada

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.